Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis

• Published in: Scientific reports Vol. 5; no. 1; p. 10585
• Main Authors: Huang, Peirong, Wang, Fenghua, Kumar Sah, Birendra, Jiang, Junhai, Ni, Zhentian, Wang, Jentso, Sun, Xiaodong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 21.07.2015; Nature Publishing Group
• Subjects: 692/499; 692/699/3161/3175; Age; Aged; Aged, 80 and over; Female; Folic acid; Folic Acid - blood; Health risk assessment; Homocysteine; Homocysteine - blood; Humanities and Social Sciences; Humans; Macular degeneration; Macular Degeneration - blood; Male; Meta-analysis; Middle Aged; multidisciplinary; Risk Factors; Science; Vitamin B 12 - blood; Vitamin B12
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep10585

Contrasting results have been reported regarding the associations between plasma total homocysteine (tHcy) and B vitamin levels and age-related macular degeneration (AMD) risk. Thus, we aimed to systematically evaluate these associations. Relevant case control studies in English were identified via a thorough search of the PubMed, Medline and Embase databases from inception to June 2014. The results were pooled using Review Manager 5.2.1. Eleven studies (including 1072 cases and 1202 controls) were eligible for analysis of tHcy levels; additionally, 3 studies (including 152 cases and 98 controls) were eligible for analysis of folic acid and vitamin B 12 levels. The cumulative results demonstrated that the plasma tHcy level among the AMD cases was 2.67 μmol/L (95% confidence interval [CI], 1.60-3.74) higher than that among the controls. In contrast, the vitamin B 12 level among the AMD cases was 64.16 pg/mL (95% CI, 19.32-109.00) lower than that among the controls. Subgroup analyses showed that the folic acid level was 1.66 ng/mL (95% CI, 0.10-3.21) lower for the wet type. Together, the results demonstrated that AMD is associated with elevated tHcy levels and decreased vitamin B 12 levels. Plasma tHcy may act as a modulator of the risk for AMD based on the current evidence.